Additional information
| Active substance | Bortezomib |
|---|---|
| Water Retention | Minimal |
| Hepatotoxicity | Low |
| Lab Test | Blood counts, liver enzymes, and renal function tests should be monitored |
| Also known as | PS-341 |
| WAREHOUSE | International Warehouse 2 |
| Blood pressure | Can cause hypotension or hypertension |
| Trade name | Velcade |
| Storage conditions | Store at 2В°C to 8В°C (36В°F to 46В°F) in original package to protect from light |
| Chemical name | [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid |
| Formula | C19H25BN4O4 |
| Substance class | Proteasome inhibitor |
| Main action | Inhibits the 26S proteasome |
| Half-life | 9 to 15 hours |
| Dosage (medical) | Typically 1.3 mg/m^2 body surface area, administered as an intravenous injection twice a week for two weeks, followed by a 10-day rest period |
| Dosage (sports) | Not applicable |
| Effects | Induces apoptosis and inhibits cell growth and proliferation |
| Side effects | Peripheral neuropathy, fatigue, gastrointestinal disturbances, thrombocytopenia, neutropenia, anemia, pyrexia |
| Use in sports | None |
| Manufacturer | Janssen-Cilag |

Zyban Glaxosmithkline
LIOTHROW cRowX Labs
Fostimon (Merional) 75 (HMG) IBSA
FACTIVE 320 mg Abdi Ibragim
Prograf 1mg Astellas Pharma
Fostimon (Merional) 150 IU HMG IBSA
Enbrel Flakon Pfizer
CANTAB PLUS 32/12.5 mg Nobel 

Reviews
There are no reviews yet.